Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Methods for the Automated Manufacturing of an Autologous Dendritic-Cell Immunotherapy
The authors developed automated equipment that uses functionally closed disposables to perform cellular and ribonucleic processing.


Pharmaceutical Technology
Volume 35, pp. s12-s17

Conclusion

These prototypes demonstrated the feasibility of this automated approach. The automated equipment and the associated disposable sets or components provides a platform technology to enable commercial manufacturing of complex autologous DC immunotherapies.

Tamara T. Monesmith is a director of manufacturing and process development at Argos Therapeutics, 4233 Technology Dr., Durham, NC 27704, tel. 919.287.6300, fax 919.287.6301,
.

References

1. J. Harris et al., Biochim. Biophys. Acta 1724 (1-2), 127–136 (2005).

2. I. Tcherepanova et al., PLoS One 1 (e1489), 1–10 (2008).

3. S.R. Bennett et al., Nature 393 (6684), 478–480 (1998).

4. J.P. Ridge, R.F. Di, and P. Matzinger, Nature 393 (6684), 474–478 (1998).

5. S.P. Schoenberger et al., Nature 393 (6684), 480–483 (1998).

6. P.T. Coates et al., Expert Rev. Mol. Med. 4 (3),1–21 (2002).

7. M.A. DeBenedette et al., J. Immunother. 34 (1), 45–57 (2011).

8. I.Y. Tcherepanova et al., BMC Mol. Biol. 9 (90), 1–13 (2008).

9. D.M. Calderhead et al., J. Immunother. 31 (8), 731-741 (2008).

10. M.A. DeBenedette et al., J. Immunol. 181 (8), 5296–5305 (2008).

11. A. Jemal et al., CA Cancer J. Clin. 60 (5), 277–300 (2010).

12. S.A. Karumanchi, J. Merchan, and V.P. Sukhatme, Curr. Opin. Nephrol. Hypertens. 11 (1), 37–42 (2002).

13. National Cancer Institute, SEER Cancer Statistics Review, 1975–2007, S.F. Altekruse et al., Eds. (NCI, Bethesda, MD, 2010).

14. K.J. Pienta and D.C. Smith, CA Cancer J. Clin. 55 (5), 300–318 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here